457 related articles for article (PubMed ID: 19180466)
1. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
2. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
3. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
6. Functional maturation of lamina propria dendritic cells by activation of NKT cells mediates the abrogation of oral tolerance.
Chang JH; Lee JM; Youn HJ; Lee KA; Chung Y; Lee AY; Kweon MN; Kim HY; Taniguchi M; Kang CY
Eur J Immunol; 2008 Oct; 38(10):2727-39. PubMed ID: 18825753
[TBL] [Abstract][Full Text] [Related]
7. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
8. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
[TBL] [Abstract][Full Text] [Related]
10. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
11. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
Shimizu K; Asakura M; Fujii S
J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
13. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
14. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin.
Gorbachev AV; Fairchild RL
Eur J Immunol; 2006 Sep; 36(9):2494-503. PubMed ID: 16909435
[TBL] [Abstract][Full Text] [Related]
15. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
17. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4.
Stegel V; Kopitar A; Jezersek Novaković B; Ihan A; Novaković S
Int Immunopharmacol; 2006 Jan; 6(1):79-89. PubMed ID: 16332516
[TBL] [Abstract][Full Text] [Related]
19. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
20. H2-D(d)-mediated upregulation of interleukin-4 production by natural killer T-cell and dendritic cell interaction.
Mizuuchi K; Yanagawa Y; Iwabuchi K; Namba K; Kitaichi N; Ohno S; Onoé K
Immunology; 2008 May; 124(1):102-11. PubMed ID: 18194275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
